AI TCR Partnerships Exogene's lab-in-the-loop AI platform, already collaborating with Immunocore to engineer TCRs, signals clear demand for AI-enabled TCR discovery and strategic co-development opportunities with pharma.

Data Gen Validation With a plan to build a core wet-lab dataset to train and validate the platform, Exogene can offer data generation and experimental validation services to de-risk AI-driven programs for potential clients.

TCR Therapy Collaboration Focus on TCR-based cell therapies creates avenues for joint development, licensing of assets, or access to Exogene's AI platform to accelerate internal and partner programs.

Platform Licensing Opportunities As a venture-backed start-up seeking pharma partnerships, Exogene could monetize through licensing its AI discovery tools, co-development deals, and milestone driven collaborations.

Regional Partnering Potential Based in Oxford with a European base, Exogene is well positioned to engage European and global biopharma partners seeking faster AI-enabled immuno-oncology solutions, leveraging credibility from its Immunocore collaboration.